Ten golden rules for optimal antibiotic use in hospital settings: the WARNING call to action

1.

Anonymous. A global declaration on appropriate use of antimicrobial agents across the surgical pathway. Surg Infect (Larchmt). 2017;18(8):846–53. https://doi.org/10.1089/sur.2017.219.CrossRef

2.

Charani E, McKee M, Ahmad R, Balasegaram M, Bonaconsa C, Merrett GB, et al. Optimising antimicrobial use in humans-review of current evidence and an interdisciplinary consensus on key priorities for research. Lancet Reg Health Eur. 2021;7:100161. https://doi.org/10.1016/j.lanepe.2021.100161.CrossRefPubMedPubMedCentral

3.

International Pharmaceutical Federation (FIP). 2009 FIP global pharmacy workforce report. 2009. https://www.fip.org/files/fip/publications/2009_FIP_Global_Pharmacy_Workforce_Report.pdf. Accessed 12 July 2023.

4.

Dhingra S, Rahman NAA, Peile E, Rahman M, Sartelli M, Hassali MA, et al. Microbial resistance movements: an overview of global public health threats posed by antimicrobial resistance, and how best to counter. Front Public Health. 2020;8:535668. https://doi.org/10.3389/fpubh.2020.535668.CrossRefPubMedPubMedCentral

5.

Dutescu IA, Hillier SA. Encouraging the development of new antibiotics: Are financial incentives the right way forward? A systematic review and case study. Infect Drug Resist. 2021;14:415–34. https://doi.org/10.2147/IDR.S287792.CrossRefPubMedPubMedCentral

6.

Renwick M, Mossialos E. What are the economic barriers of antibiotic R&D and how can we overcome them? Expert Opin Drug Discov. 2018;13(10):889–92. https://doi.org/10.1080/17460441.2018.1515908.CrossRefPubMed

7.

Renwick MJ, Brogan DM, Mossialos E. A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics. J Antibiot (Tokyo). 2016;69(2):73–88. https://doi.org/10.1038/ja.2015.98.CrossRefPubMed

8.

Jamrozik E, Selgelid M, editors. Ethics and drug resistance: collective responsibility for global public health. Heidelberg: Springer; 2020.

9.

Plachouras D, Kärki T, Hansen S, Hopkins S, Lyytikäinen O, Moro ML, Point Prevalence Survey Study Group, et al. Antimicrobial use in European acute care hospitals: Results from the second point prevalence survey (PPS) of healthcare-associated infections and antimicrobial use, 2016 to 2017. Euro Surveill. 2018;23(46):1800393. https://doi.org/10.2807/1560-7917.ES.23.46.1800393.CrossRefPubMedPubMedCentral

10.

Fridkin S, Baggs J, Fagan R, Magill S, Pollack LA, Malpiedi P, Centers for Disease Control and Prevention (CDC), et al. Vital signs: improving antibiotic use among hospitalized patients. MMWR Morb Mortal Wkly Rep. 2014;63(9):194–200.PubMedPubMedCentral

11.

Geller AI, Lovegrove MC, Shehab N, Hicks LA, Sapiano MRP, Budnitz DS. National estimates of emergency department visits for antibiotic adverse events among adults-United States, 2011–2015. J Gen Intern Med. 2018;33(7):1060–8. https://doi.org/10.1007/s11606-018-4430-x.CrossRefPubMedPubMedCentral

12.

Bauer KA, Kullar R, Gilchrist M, File TM Jr. Antibiotics and adverse events: the role of antimicrobial stewardship programs in “doing no harm.” Curr Opin Infect Dis. 2019;32(6):553–8. https://doi.org/10.1097/QCO.0000000000000604.CrossRefPubMed

13.

Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of adverse events with antibiotic use in hospitalized patients. JAMA Intern Med. 2017;177(9):1308–15. https://doi.org/10.1001/jamainternmed.2018.6226.CrossRefPubMedPubMedCentral

14.

Silva ML, Cargnello C, Aulois-Griot M, Dumartin C. Antibiotic misuse: How to evaluate the costs? Med Mal Infect. 2019;49(7):485–94. https://doi.org/10.1016/j.medmal.2019.03.012.CrossRefPubMed

15.

Baur D, Gladstone BP, Burkert F, Carrara E, Foschi F, Döbele S, et al. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17(9):990–1001. https://doi.org/10.1016/S1473-3099(17)30325-0.CrossRefPubMed

16.

Global Alliance for Infections in Surgery. https://www.infectionsinsurgery.org. Accessed 12 July 2023.

17.

Dahiya S, Chhillar AK, Sharma N, Choudhary P, Punia A, Balhara M, et al. Candida auris and nosocomial infection. Curr Drug Targets. 2020;21(4):365–73. https://doi.org/10.2174/1389450120666190924155631.CrossRefPubMed

18.

Dubey AK, Singla RK. Perspectives on anti-Candida drug development. Curr Top Med Chem. 2019;19:2375–6. https://doi.org/10.2174/156802661928191206162925.CrossRefPubMed

19.

Vassilopoulos S, Mylonakis E. Avenues for antifungal drug discovery and development: Where to now? Expert Opin Drug Discov. 2022;17:667–72. https://doi.org/10.1080/17460441.2022.2098950.CrossRefPubMed

20.

CDC. Antibiotic resistance threats in the United States, 2019. Atlanta: U.S. Department of Health and Human Services, CDC; 2019. www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf. Accessed 12 July 2023.

21.

Lyman M, Forsberg K, Sexton DJ, Chow NA, Lockhart SR, Jackson BR, et al. Worsening spread of Candida auris in the United States, 2019 to 2021. Ann Intern Med. 2023;176(4):489–95. https://doi.org/10.7326/M22-3469.CrossRefPubMed

22.

Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. Candida auris sp. Nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009;53:41–4. https://doi.org/10.1111/j.1348-0421.2008.00083.x.CrossRefPubMed

23.

Kim MN, Shin JH, Sung H, Lee K, Kim EC, Ryoo N, et al. Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features. Clin Infect Dis. 2009;48:e57–61. https://doi.org/10.1086/597108.CrossRefPubMed

24.

van Schalkwyk E, Mpembe RS, Thomas J, Shuping L, Ismail H, Lowman W, GERMS-SA, et al. Epidemiologic shift in candidemia driven by Candida auris, South Africa, 2016–2017. Emerg Infect Dis. 2019;25:1698–707. https://doi.org/10.3201/eid2509.190040.CrossRefPubMedPubMedCentral

25.

Vallabhaneni S, Kallen A, Tsay S, Chow N, Welsh R, Kerins J, et al. Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrug-resistant fungus-United States, May 2013-August 2016. Am J Transplant. 2017;17:296–9. https://doi.org/10.1111/ajt.14121.CrossRefPubMed

26.

Borman AM, Szekely A, Johnson EM. Comparative pathogenicity of United Kingdom isolates of the emerging pathogen Candida auris and other key pathogenic Candida species. mSphere. 2016;1(4):e00189-e216. https://doi.org/10.1128/mSphere.00189-16.CrossRefPubMedPubMedCentral

27.

Cortegiani A, Misseri G, Fasciana T, Giammanco A, Giarratano A, Chowdhary A. Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris. J Intensive Care. 2018;6:69. https://doi.org/10.1186/s40560-018-0342-4.CrossRefPubMedPubMedCentral

28.

Spivak ES, Hanson KE. Candida auris: an emerging fungal pathogen. J Clin Microbiol. 2018;56(2):e01588-e1617. https://doi.org/10.1128/JCM.01588-17.CrossRefPubMedPubMedCentral

29.

Kean R, Brown J, Gulmez D, Ware A, Ramage G. Candida auris: a decade of understanding of an enigmatic pathogenic yeast. J Fungi (Basel). 2020;6(1):30. https://doi.org/10.3390/jof6010030.CrossRefPubMed

30.

Lee WG, Shin JH, Uh Y, Kang MG, Kim SH, Park KH, et al. First three reported cases of nosocomial fungemia caused by Candida auris. J Clin Microbiol. 2011;49(9):3139–42. https://doi.org/10.1128/JCM.00319-11.CrossRefPubMedPubMedCentral

31.

Rossato L, Colombo AL. Candida auris: What have we learned about its mechanisms of pathogenicity? Front Microbiol. 2018;9:3081. https://doi.org/10.3389/fmicb.2018.03081.CrossRefPubMedPubMedCentral

32.

Yue H, Bing J, Zheng Q, Zhang Y, Hu T, Du H, et al. Filamentation in Candida auris, an emerging fungal pathogen of humans: passage through the mammalian body induces a heritable phenotypic switch. Emerg Microbes Infect. 2018;7(1):188. https://doi.org/10.1038/s41426-018-0187-x.CrossRefPubMedPubMedCentral

33.

Mayer FL, Wilson D, Hube B. Candida albicans pathogenicity mechanisms. Virulence. 2013;4(2):119–28. https://doi.org/10.4161/viru.22913.CrossRefPubMedPubMedCentral

34.

Sartelli M, Weber DG, Ruppé E, Bassetti M, Wright BJ, Ansaloni L, et al. Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA). World J Emerg Surg. 2016;11:33. https://doi.org/10.1186/s13017-016-0089-y.CrossRefPubMedPubMedCentral

35.

El-Halfawy OM, Valvano MA. Antimicrobial heteroresistance: an emerging field in need of clarity. Clin Microbiol Rev. 2015;28(1):191–207. https://doi.org/10.1128/CMR.00058-14.CrossRefPubMedPubMedCentral

36.

Andersson DI, Nicoloff H, Hjort K. Mechanisms and clinical relevance of bacterial heteroresistance. Nat Rev Microbiol. 2019;17(8):479–96. https://doi.org/10.1038/s41579-019-0218-1.CrossRefPubMed

37.

Roca I, Akova M, Baquero F, Carlet J, Cavaleri M, Coenen S, et al. The global threat of antimicrobial resistance: science for intervention. New Microbes New Infect. 2015;6:22–9. https://doi.org/10.1016/j.nmni.2015.02.007.CrossRefPubMedPubMedCentral

38.

Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE. J Infect Dis. 2008;197(8):1079–81. https://doi.org/10.1086/533452.CrossRefPubMed

39.

Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1–12. https://doi.org/10.1086/595011.CrossRefPubMed

40.

Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–81. https://doi.org/10.1111/j.1469-0691.2011.03570.x.CrossRefPubMed

41.

Kadri SS, Adjemian J, Lai YL, Spaulding AB, Ricotta E, Prevots DR, National Institutes of Health Antimicrobial Resistance Outcomes Research Initiative (NIH–ARORI), et al. Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: Retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents. Clin Infect Dis. 2018;67(12):1803–14. https://doi.org/10.1093/cid/ciy378.CrossRefPubMedPubMedCentral

42.

Iskandar K, Molinier L, Hallit S, Sartelli M, Catena F, Coccolini F, et al. Drivers of antibiotic resistance transmission in low- and middle-income countries from a “one health” perspective-a review. Antibiotics (Basel). 2020;9(7):372. https://doi.org/10.3390/antibiotics9070372.CrossRefPubMed

43.

Hollis A, Maybarduk P. Antibiotic resistance is a tragedy of the commons that necessitates global cooperation. J Law Med Ethics. 2015;43(Suppl 3):33–7.CrossRefPubMed

44.

One Health High-Level Expert Panel (OHHLEP), Adisasmito WB, Almuhairi S, Behravesh CB, Bilivogui P, Bukachi SA, et al. One Health: A new definition for a sustainable and healthy future. PLoS Pathog. 2022;18(6):e1010537. https://doi.org/10.1371/journal.ppat.1010537.CrossRef

45.

Venter H, Henningsen ML, Begg SL. Antimicrobial resistance in healthcare, agriculture and the environment: the biochemistry behind the headlines. Essays Biochem. 2017;61(1):1–10. https://doi.org/10.1042/EBC20160053.CrossRefPubMedPubMedCentral

46.

Crisci E. From open access to circular health: Ilaria Capua’s journey through science and politics. Viruses. 2022;14(6):1296. https://doi.org/10.3390/v14061296.CrossRefPubMedPubMedCentral

47.

Boudreau LeBlanc A, Williams-Jones B, Aenishaenslin C. Bioethics and one health: a case study approach to building reflexive governance. Front Public Health. 2022;18:311. https://doi.org/10.3389/fpubh.2022.648593.CrossRef

48.

Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, et al. Antibiotic resistance-the need for global solutions. Lancet Infect Dis. 2013;13(12):1057–98. https://doi.org/10.1016/s1473-3099(13)70318-9.CrossRefPubMed

49.

WHO. World Health Organization global action plan on antimicrobial resistance. 2015. https://www.who.int/publications/i/item/9789241509763. Accessed 12 July 2023.

50.

Charani E, Mendelson M, Pallett SJC, Ahmad R, Mpundu M, Mbamalu O, et al. An analysis of existing national action plans for antimicrobial resistance-gaps and opportunities in strategies optimising antibiotic use in human populations. Lancet Glob Health. 2023;11(3):e466–74. https://doi.org/10.1016/S2214-109X(23)00019-0.CrossRefPubMed

51.

Patel J, Harant A, Fernandes G, Mwamelo AJ, Hein W, Dekker D, et al. Measuring the global response to antimicrobial resistance, 2020–21: a systematic governance analysis of 114 countries. Lancet Infect Dis. 2023;3(6):706–18. https://doi.org/10.1016/S1473-3099(22)00796-4.CrossRef

52.

Patel J, Sridhar D. The pandemic legacy of antimicrobial resistance in the USA. Lancet Microbe. 2022;3(10):e726–7. https://doi.org/10.1016/S2666-5247(22)00227-0.CrossRefPubMedPubMedCentral

53.

Nandi A, Pecetta S, Bloom DE. Global antibiotic use during the COVID-19 pandemic: analysis of pharmaceutical sales data from 71 countries, 2020–2022. EClinicalMedicine. 2023;57:101848. https://doi.org/10.1016/j.eclinm.2023.101848.CrossRefPubMedPubMedCentral

54.

Langford BJ, So M, Simeonova M, Leung V, Lo J, Kan T, et al. Antimicrobial resistance in patients with COVID-19: a systematic review and meta-analysis. Lancet Microbe. 2023;4(3):e179–91. https://doi.org/10.1016/S2666-5247(22)00355-X.CrossRefPubMedPubMedCentral

55.

Brink AJ, Richards G, Tootla H, Prentice E. Epidemiology of Gram-negative bacteria during coronavirus disease 2019. What is the real pandemic? Curr Opin Infect Dis. 2022;35(6):595–604. https://doi.org/10.1097/QCO.0000000000000864.CrossRefPubMed

56.

Langford BJ, Soucy JR, Leung V, So M, Kwan ATH, Portnoff JS, et al. Antibiotic resistance associated with the COVID-19 pandemic: a systematic review and meta-analysis. Clin Microbiol Infect. 2022. https://doi.org/10.1016/j.cmi.2022.12.006.CrossRefPubMedPubMedCentral

57.

Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–55. https://doi.org/10.1016/S0140-6736(21)02724-0.CrossRef

58.

Laxminarayan R. The overlooked pandemic of antimicrobial resistance. Lancet. 2022;399(10325):606–7. https://doi.org/10.1016/S0140-6736(22)00087-3.CrossRefPubMedPubMedCentral

59.

Makoka MH, Miller WC, Hoffman IF, Cholera R, Gilligan PH, Kamwendo D, et al. Bacterial infections in Lilongwe, Malawi: Aetiology and antibiotic resistance. BMC Infect Dis. 2012;12:67. https://doi.org/10.1186/1471-2334-12-67.CrossRefPubMedPubMedCentral

60.

Ouedraogo AS, Jean Pierre H, Bañuls AL, Ouédraogo R, Godreuil S. Emergence and spread of antibiotic resistance in West Africa: contributing factors and threat assessment. Med Sante Trop. 2017;27(2):147–54. https://doi.org/10.1684/mst.2017.0678.CrossRefPubMed

61.

Lancet T. Redefining vulnerability in the era of COVID-19. Lancet. 2020;395(10230):1089. https://doi.org/10.1016/S0140-6736(20)30757-1.CrossRef

62.

Alividza V, Mariano V, Ahmad R, Charani E, Rawson TM, Holmes AH, et al. Investigating the impact of poverty on colonization and infection with drug-resistant organisms in humans: a systematic review. Infect Dis Poverty. 2018;7(1):76. https://doi.org/10.1186/s40249-018-0459-7.CrossRefPubMedPubMedCentral

63.

Holmes AH, Sharland M. The Chennai Declaration: India’s landmark national commitment to antibiotic stewardship demonstrates that “truth alone triumphs.” J Antimicrob Chemother. 2013;68(7):1453–4.CrossRefPubMed

64.

O’Neill J. Tackling drug-resistant infections globally: final report and recommendations. The review on antimicrobial resistance. 2016. https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf. Accessed 12 July 2023.

65.

Jonas O, Irwin A, Berthe FCJ, Le Gall FG, Marquez PV. Drug-resistant infections: a threat to our economic future (vol 2): final report (English). HNP/Agriculture Global Antimicrobial Resistance Initiative Washington, D.C.: World Bank Group. http://documents.worldbank.org/curated/en/323311493396993758/final-report. Accessed 12 July 2023.

66.

de Kraker ME, Stewardson AJ, Harbarth S. Will 10 million people die a year due to antimicrobial resistance by 2050? PLoS Med. 2016;13(11):e1002184. https://doi.org/10.1371/journal.pmed.1002184.CrossRefPubMedPubMedCentral

67.

Global Health Hub Germany. Results of the G7 health ministers’ meeting in Berlin, 19–20 May 2022. https://www.globalhealthhub.de/de/news/detail/g7-health-ministers-unite-to-secure-a-healthy-future-results-of-the-g7-health-ministers-meeting-in-berlin-may-19-20-2022. Accessed 12 July 2023

68.

Anderson M, Schulze K, Cassini A, Plachouras D, Mossialos E. A governance framework for development and assessment of national action plans on antimicrobial resistance. Lancet Infect Dis. 2019;19(11):e371–84. https://doi.org/10.1016/S1473-3099(19)30415-3.CrossRefPubMed

69.

Kiggundu R, Lusaya E, Seni J, Waswa JP, Kakooza F, Tjipura D, et al. Identifying and addressing challenges to antimicrobial use surveillance in the human health sector in low- and middle-income countries: experiences and lessons learned from Tanzania and Uganda. Antimicrob Resist Infect Control. 2023;12(1):9. https://doi.org/10.1186/s13756-023-01213-3.CrossRefPubMedPubMedCentral

70.

Ren M, So AD, Chandy SJ, Mpundu M, Peralta AQ, Åkerfeldt K, et al. Equitable access to antibiotics: a core element and shared global responsibility for pandemic preparedness and response. J Law Med Ethics. 2022;50(S2):34–9. https://doi.org/10.1017/jme.2022.77.CrossRefPubMedPubMedCentral

71.

Broom A, Kenny K, Prainsack B, Broom J. Antimicrobial resistance as a problem of values? Views from three continents. Crit Public Health. 2021;31(4):451–63. https://doi.org/10.1080/09581596.2020.1725444.CrossRef

72.

Council of the EU and the European Council. Tackling antimicrobial resistance: council adopts recommendation. https://www.consilium.europa.eu/en/press/press-releases/2023/06/13/tackling-antimicrobial-resistance-council-adopts-recommendation/. Accessed 12 July 2023.

73.

Ndaki PM, Mushi MF, Mwanga JR, Konje ET, Ntinginya NE, Mmbaga BT, et al. Dispensing antibiotics without prescription at community pharmacies and accredited drug dispensing outlets in Tanzania: a cross-sectional study. Antibiotics (Basel). 2021;10(8):1025. https://doi.org/10.3390/antibiotics10081025.CrossRefPubMed

74.

Kaprou GD, Bergšpica I, Alexa EA, Alvarez-Ordóñez A, Prieto M. Rapid methods for antimicrobial resistance diagnostics. Antibiotics (Basel). 2021;10(2):209. https://doi.org/10.3390/antibiotics10020209.CrossRefPubMed

75.

Charani E, Ahmad R, Rawson TM, Castro-Sanchèz E, Tarrant C, Holmes AH. The differences in antibiotic decision-making between acute surgical and acute medical teams: an ethnographic study of culture and team dynamics. Clin Infect Dis. 2019;69(1):12–20. https://doi.org/10.1093/cid/ciy844.CrossRefPubMed

76.

Cantón R, Horcajada JP, Oliver A, Garbajosa PR, Vila J. Inappropriate use of antibiotics in hospitals: the complex relationship between antibiotic use and antimicrobial resistance. Enferm Infecc Microbiol Clin. 2013;31(Suppl 4):3–11. https://doi.org/10.1016/S0213-005X(13)70126-5.CrossRefPubMed

77.

Levy Hara G, Rojas-Cortés R, Molina León HF, Dreser Mansilla A, Alfonso Orta I, Rizo-Amezquita JN, et al. Point prevalence survey of antibiotic use in hospitals in Latin American countries. J Antimicrob Chemother. 2022;77(3):807–15. https://doi.org/10.1093/jac/dkab459.CrossRefPubMed

78.

Sartelli M, Duane TM, Catena F, Tessier JM, Coccolini F, Kao LS, et al. Antimicrobial stewardship: a call to action for surgeons. Surg Infect (Larchmt). 2016;17(6):625–31. https://doi.org/10.1089/sur.2016.187.CrossRefPubMed

79.

Goff DA, Kullar R, Goldstein EJC, Gilchrist M, Nathwani D, Cheng AC, et al. A global call from five countries to collaborate in antibiotic stewardship: United we succeed, divided we might fail. Lancet Infect Dis. 2017;17(2):e56–63. https://doi.org/10.1016/S1473-3099(16)30386-3.CrossRefPubMed

80.

Doron S, Davidson LE. Antimicrobial stewardship. Mayo Clin Proc. 2011;86(11):1113–23. https://doi.org/10.4065/mcp.2011.0358.CrossRefPubMedPubMedCentral

81.

Dyar OJ, Huttner B, Schouten J, Pulcini C, ESGAP (ESCMID Study Group for Antimicrobial stewardshiP). What is antimicrobial stewardship? Clin Microbiol Infect. 2017;23(11):793–8. https://doi.org/10.1016/j.cmi.2017.08.026.CrossRefPubMed

82.

Kpokiri EE, Ladva M, Dodoo CC, Orman E, Aku TA, Mensah A, et al. Knowledge, awareness and practice with antimicrobial stewardship programmes among healthcare providers in a Ghanaian tertiary hospital. Antibiotics (Basel). 2021;11(1):6. https://doi.org/10.3390/antibiotics11010006.CrossRefPubMedPubMedCentral

83.

Retamar P, Rodríguez-Baño J. A step forward in the definition of antimicrobial stewardship indicators: better measurements, better work. Farm Hosp. 2019;43(3):77–8. https://doi.org/10.7399/fh.11238.CrossRefPubMed

84.

Dryden M, Johnson AP, Ashiru-Oredope D, Sharland M. Using antibiotics responsibly: right drug, right time, right dose, right duration. J Antimicrob Chemother. 2011;66(11):2441–3. https://doi.org/10.1093/jac/dkr370.CrossRefPubMed

85.

Kakkar AK, Shafiq N, Singh G, Ray P, Gautam V, Agarwal R, et al. Antimicrobial stewardship programs in resource constrained environments: understanding and addressing the need of the systems. Front Public Health. 2020;8:140. https://doi.org/10.3389/fpubh.2020.00140.CrossRefPubMedPubMedCentral

86.

Godman B, Egwuenu A, Haque M, Malande OO, Schellack N, Kumar S, et al. Strategies to improve antimicrobial utilization with a special focus on developing countries. Life (Basel). 2021;11(6):528. https://doi.org/10.3390/life11060528.CrossRefPubMed

87.

Dyar OJ, Moran-Gilad J, Greub G, Pulcini C, ESGMD Executive Committee and the ESGAP Executive Committee. Diagnostic stewardship: Are we using the right term? Clin Microbiol Infect. 2019;25(3):272–3. https://doi.org/10.1016/j.cmi.2018.12.011.CrossRefPubMed

88.

Patel R, Fang FC. Diagnostic stewardship: opportunity for a laboratory-infectious diseases partnership. Clin Infect Dis. 2018;67(5):799–801. https://doi.org/10.1093/cid/ciy077.\.CrossRefPubMedPubMedCentral

89.

Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44(2):159–77. https://doi.org/10.1086/510393.CrossRefPubMed

90.

Vieceli T, Rello J. Optimization of antimicrobial prescription in the hospital. Eur J Intern Med. 2022;106:39–44. https://doi.org/10.1016/j.ejim.2022.08.035.CrossRefPubMed

91.

Safdar N, Abad C. Educational interventions for prevention of healthcare-associated infection: a systematic review. Crit Care Med. 2008;36(3):933–40. https://doi.org/10.1097/CCM.0B013E318165FAF3.CrossRefPubMed

92.

Ward DJ. The role of education in the prevention and control of infection: a review of the literature. Nurse Educ Today. 2011;31(1):9–17. https://doi.org/10.1016/j.nedt.2010.03.007.CrossRefPubMed

93.

Carlet J, Astagneau P, Brun-Buisson C, Coignard B, Salomon V, Tran B, French National Program for Prevention of Healthcare-Associated Infections and Antimicrobial Resistance, et al. French national program for prevention of healthcare-associated infections and antimicrobial resistance, 1992–2008: positive trends, but perseverance needed. Infect Control Hosp Epidemiol. 2009;30(8):737–45. https://doi.org/10.1086/598682.CrossRefPubMed

94.

Alhumaid S, Al Mutair A, Al Alawi Z, Alsuliman M, Ahmed GY, Rabaan AA, et al. Knowledge of infection prevention and control among healthcare workers and factors influencing compliance: a systematic review. Antimicrob Resist Infect Control. 2021;10(1):86. https://doi.org/10.1186/s13756-021-00957-0.CrossRefPubMedPubMedCentral

95.

Sartelli M, Pagani L, Iannazzo S, Moro ML, Viale P, Pan A, et al. A proposal for a comprehensive approach to infections across the surgical pathway. World J Emerg Surg. 2020;15(1):13. https://doi.org/10.1186/s13017-020-00295-3.CrossRefPubMedPubMedCentral

96.

Sartelli M, Labricciosa FM, Coccolini F, Coimbra R, Abu-Zidan FM, Ansaloni L, et al. It is time to define an organizational model for the prevention and management of infections along the surgical pathway: a worldwide cross-sectional survey. World J Emerg Surg. 2022;17(1):17. https://doi.org/10.1186/s13017-020-00295-3.CrossRefPubMedPubMedCentral

97.

Cassini A, Högberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, Burden of AMR Collaborative Group, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: A population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56–66. https://doi.org/10.1016/S1473-3099(18)30605-4.CrossRefPubMedPubMedCentral

98.

Suetens C, Latour K, Kärki T, Ricchizzi E, Kinross P, Moro ML, et al. Prevalence of healthcare-associated infections, estimated incidence and composite antimicrobial resistance index in acute care hospitals and long-term care facilities: results from two European point prevalence surveys, 2016 to 2017. Euro Surveill. 2018;23(46):1800516. https://doi.org/10.2807/1560-7917.ES.2018.23.46.1800516.CrossRefPubMedPubMedCentral

99.

Cassini A, Plachouras D, Eckmanns T, Abu Sin M, Blank HP, Ducomble T, et al. Burden of six healthcare-associated infections on European population health: estimating incidence-based disability-adjusted life years through a population prevalence-based modelling study. PLoS Med. 2016;13(10):e1002150. https://doi.org/10.1371/journal.pmed.1002150.CrossRefPubMedPubMedCentral

100.

Schreiber PW, Sax H, Wolfensberger A, Clack L, Kuster SP, Swissnoso. The preventable proportion of healthcare-associated infections 2005–2016: systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2018;39:1277–95. https://doi.org/10.1017/ice.2018.183.CrossRefPubMed

101.

World Health Organization. WHO guidelines on hand hygiene in health care. Geneva: World Health Organization; 2009. https://www.who.int/publications/i/item/9789241597906. Accessed 12 July 2023.

102.

Boyce JM, Pittet D, Healthcare Infection Control Practices Advisory Committee, HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Guideline for hand hygiene in health-care settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. MMWR Recomm Rep. 2002;51(16):1–45.PubMed

103.

Glowicz JB, Landon E, Sickbert-Bennett EE, Aiello AE, deKay K, Hoffmann KK, et al. SHEA/IDSA/APIC practice recommendation: strategies to prevent healthcare-associated infections through hand hygiene: 2022 Update. Infect Control Hosp Epidemiol. 2023;44(3):355–76. https://doi.org/10.1017/ice.2022.304.CrossRefPubMedPubMedCentral

104.

Sax H, Allegranzi B, Uçkay I, Larson E, Boyce J, Pittet D. “My five moments for hand hygiene”: a user-centred design approach to understand, train, monitor and report hand hygiene. J Hosp Infect. 2007;67(1):9–21. https://doi.org/10.1016/j.jhin.2015.04.011.CrossRefPubMed

105.

Erasmus V, Daha TJ, Brug H, Richardus JH, Behrendt MD, Vos MC, et al. Systematic review of studies on compliance with hand hygiene guidelines in hospital care. Infect Control Hosp Epidemiol. 2010;31(3):283–94. https://doi.org/10.1086/650451.CrossRefPubMed

106.

Kirk J, Kendall A, Marx JF, Pincock T, Young E, Hughes JM, Landers T. Point of care hand hygiene-where’s the rub? A survey of US and Canadian health care workers’ knowledge, attitudes, and practices. Am J Infect Control. 2016;44(10):1095–101. https://doi.org/10.1016/j.ajic.2016.03.005.CrossRefPubMed

107.

Allegranzi B, Zayed B, Bischoff P, Kubilay NZ, de Jonge S, de Vries F, et al. New WHO recommendations on intraoperative and postoperative measures for surgical site infection prevention: an evidence-based global perspective. Lancet Infect Dis. 2016;16:e288-303. https://doi.org/10.1016/S1473-3099(16)30402-9.CrossRefPubMed

108.

Allegranzi B, Bischoff P, de Jonge S, Kubilay NZ, Zayed B, Gomes SM, et al. New WHO recommendations on preoperative measures for surgical site infection prevention: an evidence-based global perspective. Lancet Infect Dis. 2016;16:e276-287. https://doi.org/10.1016/S1473-3099(16)30398-X.CrossRefPubMed

109.

Berríos-Torres SI, Umscheid CA, Bratzler DW, Leas B, Stone EC, Kelz RR, et al. Centers for Disease Control and Prevention guideline for the prevention of surgical site infection, 2017. JAMA Surg. 2017;152:784–91. https://doi.org/10.1001/jamasurg.2017.0904.CrossRefPubMed

110.

World Health Organization. Guidelines on core components of infection prevention and control programmes at the national and acute health care facility level. Geneva: World Health Organization; 2016. https://apps.who.int/iris/handle/10665/251730. Accessed 12 July 2023.

111.

Storr J, Twyman A, Zingg W, Damani N, Kilpatrick C, Reilly J, et al. Core components for effective infection prevention and control programmes: new WHO evidence-based recommendations. Antimicrob Resist Infect Control. 2017;6:6. https://doi.org/10.1186/s13756-016-0149-9.CrossRefPubMedPubMedCentral

112.

Sydnor ER, Perl TM. Hospital epidemiology and infection control in acute-care settings. Clin Microbiol Rev. 2011;24(1):141–73. https://doi.org/10.1128/CMR.00027-10.CrossRefPubMedPubMedCentral

113.

Zingg W, Holmes A, Dettenkofer M, Goetting T, Secci F, Clack L, et al. Hospital organisation, management, and structure for prevention of health-care-associated infection: a systematic review and expert consensus. Lancet Infect Dis. 2015;15(2):212–24. https://doi.org/10.1016/S1473-3099(14)70854-0.CrossRefPubMed

114.

Tomczyk S, Twyman A, de Kraker MEA, Coutinho Rehse AP, Tartari E, Toledo JP, et al. The first WHO global survey on infection prevention and control in health-care facilities. Lancet Infect Dis. 2022;22(6):845–56. https://doi.org/10.1016/S1473-3099(21)00809-4.CrossRefPubMedPubMedCentral

115.

Brink AJ, Richards GA. Antimicrobial stewardship: leveraging the “butterfly effect” of hand hygiene. Antibiotics (Basel). 2022;11(10):1348. https://doi.org/10.3390/antibiotics11101348.CrossRefPubMed

116.

Mills JP, Marchaim D. Multidrug-resistant gram-negative bacteria: infection prevention and control update. Infect Dis Clin N Am. 2021;35(4):969–94. https://doi.org/10.1016/j.idc.2021.08.001.CrossRef

117.

Guidelines for the prevention and control of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in health care facilities. Geneva: World Health Organization; 2017. https://www.ncbi.nlm.nih.gov/books/NBK493061/. Accessed 12 July 2023.

118.

Tomczyk S, Zanichelli V, Grayson ML, Twyman A, Abbas M, Pires D, et al. Control of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa in healthcare facilities: a systematic review and reanalysis of quasi-experimental studies. Clin Infect Dis. 2019;68(5):873–84. https://doi.org/10.1093/cid/ciy752.CrossRefPubMed

119.

Micoli F, Bagnoli F, Rappuoli R, Serruto D. The role of vaccines in combatting antimicrobial resistance. Nat Rev Microbiol. 2021;19(5):287–302. https://doi.org/10.1038/s41579-020-00506-3.CrossRefPubMedPubMedCentral

120.

Merakou C, Schaefers MM, Priebe GP. Progress toward the elusive Pseudomonas aeruginosa vaccine. Surg Infect (Larchmt). 2018;19(8):757–68. https://doi.org/10.1089/sur.2018.233.CrossRefPubMed

121.

Barie PS, Narayan M, Sawyer RG. Immunization against Staphylococcus aureus infections. Surg Infect (Larchmt). 2018;19(8):750–6. https://doi.org/10.1089/sur.2018.263.CrossRefPubMed

122.

Sihvonen R, Siira L, Toropainen M, Kuusela P, Patari-Sampo A. Streptococcus pneumoniae antimicrobial resistance decreased in the Helsinki metropolitan area after routine 10-valent pneumococcal conjugate vaccination of infants in Finland. Eur J Clin Microbiol Infect Dis. 2017;36:2109–16. https://doi.org/10.1007/s10096-017-3033-5.CrossRefPubMed

123.

Jansen KU, Anderson AS. The role of vaccines in fighting antimicrobial resistance (AMR). Hum Vaccin Immunother. 2018;14(9):2142–9. https://doi.org/10.1080/21645515.2018.1476814.CrossRefPubMedPubMedCentral

124.

Tekle YI, Nielsen KM, Liu J, Pettigrew MM, Meyers LA, Galvani AP, et al. Controlling antimicrobial resistance through targeted, vaccine-induced replacement of strains. PLoS ONE. 2012;7:e50688. https://doi.org/10.1371/journal.pone.0050688.CrossRefPubMedPubMedCentral

125.

Mina MJ, Kula T, Leng Y, Li M, de Vries RD, Knip M, et al. Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens. Science. 2019;366(6465):599–606. https://doi.org/10.1126/science.aay6485.CrossRefPubMedPubMedCentral

126.

Dionne B, Dehority W, Brett M, Howdieshell TR. The asplenic patient: post-insult immunocompetence, infection, and vaccination. Surg Infect (Larchmt). 2017;18(5):536–44. https://doi.org/10.1089/sur.2016.267.CrossRefPubMed

127.

Gabutti G. Available evidence and potential for vaccines for reduction in antibiotic prescriptions. Hum Vaccin Immunother. 2022;18(7):2151291. https://doi.org/10.1080/21645515.2022.2151291.CrossRefPubMedPubMedCentral

128.

Kim S, Covington A, Pamer EG. The intestinal microbiota: antibiotics, colonization resistance, and enteric pathogens. Immunol Rev. 2017;279(1):90–105. https://doi.org/10.1111/imr.12563.CrossRefPubMedPubMedCentral

129.

Donskey CJ. Antibiotic regimens and intestinal colonization with antibiotic-resistant gram-negative bacilli. Clin Infect Dis. 2006;43(Suppl 2):S62–9. https://doi.org/10.1086/504481.CrossRefPubMed

130.

Salyers AA, Gupta A, Wang Y. Human intestinal bacteria as reservoirs for antibiotic resistance genes. Trends Microbiol. 2004;12:412–6. https://doi.org/10.1016/j.tim.2004.07.004.CrossRefPubMed

131.

Bhalla A, Pultz NJ, Ray AJ, Hoyen CK, Eckstein EC, Donskey CJ. Antianaerobic antibiotic therapy promotes overgrowth of antibiotic-resistant, gram-negative bacilli and vancomycin-resistant enterococci in the stool of colonized patients. Infect Control Hosp Epidemiol. 2003;24(9):644–9. https://doi.org/10.1086/502267.CrossRefPubMed

132.

Donskey CJ, Chowdhry TK, Hecker MT, Hoyen CK, Hanrahan JA, Hujer AM, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med. 2000;343(26):1925–32. https://doi.org/10.1056/NEJM200012283432604.CrossRefPubMedPubMedCentral

133.

Taur Y, Xavier JB, Lipuma L, Ubeda C, Goldberg J, Gobourne A, et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2012;55(7):905–14. https://doi.org/10.1093/cid/cis580.CrossRefPubMedPubMedCentral

134.

Ruppé E, Lixandru B, Cojocaru R, Büke C, Paramythiotou E, Angebault C, et al. Relative fecal abundance of extended-spectrum-β-lactamase-producing Escherichia coli strains and their occurrence in urinary tract infections in women. Antimicrob Agents Chemother. 2013;57(9):4512–7. https://doi.org/10.1128/AAC.00238-13.CrossRefPubMedPubMedCentral

135.

Rashid MU, Zaura E, Buijs MJ, Keijser BJ, Crielaard W, Nord CE, et al. Determining the long-term effect of antibiotic administration on the human normal intestinal microbiota using culture and pyrosequencing methods. Clin Infect Dis. 2015;60(Suppl 2):S77–84. https://doi.org/10.1093/cid/civ137.CrossRefPubMed

136.

Lindgren M, Lofmark S, Edlund C, Huovinen P, Jalava J. Prolonged impact of a one-week course of clindamycin on Enterococcus spp. in human normal microbiota. Scand J Infect Dis. 2009;41(3):215–9. https://doi.org/10.1080/00365540802651897.CrossRefPubMed

137.

Patangia DV, Anthony Ryan C, Dempsey E, Paul Ross R, Stanton C. Impact of antibiotics on the human microbiome and consequences for host health. Microbiol Open. 2022;11(1):e1260. https://doi.org/10.1002/mbo3.1260.CrossRef

138.

De La Cochetière MF, Durand T, Lepage P, Bourreille A, Galmiche JP, Doré J. Resilience of the dominant human fecal microbiota upon short-course antibiotic challenge. J Clin Microbiol. 2005;43(11):5588–92. https://doi.org/10.1128/JCM.43.11.5588-5592.2005.CrossRefPubMed

139.

Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 2008;6(11):e280. https://doi.org/10.1371/journal.pbio.0060280.CrossRefPubMedPubMedCentral

140.

Raymond F, Ouameur AA, Déraspe M, Iqbal N, Gingras H, Dridi B, et al. The initial state of the human gut microbiome determines its reshaping by antibiotics. ISME J. 2016;10(3):707–20. https://doi.org/10.1038/ismej.2015.148.CrossRefPubMed

141.

Zhang L, Huang Y, Zhou Y, Buckley T, Wang HH. Antibiotic administration routes significantly influence the levels of antibiotic resistance in gut microbiota. Antimicrob Agents Chemother. 2013;57(8):3659–66. https://doi.org/10.1128/AAC.00670-13.CrossRefPubMedPubMedCentral

142.

Solbach P, Chhatwal P, Woltemate S, Tacconelli E, Buhl M, Autenrieth IB, et al. Microbiota-associated risk factors for Clostridioides difficile acquisition in hospitalized patients: a prospective, multicentric study. Clin Infect Dis. 2021;73(9):e2625–34. https://doi.org/10.1093/cid/ciaa871.CrossRefPubMed

143.

Aguilar RC, Salmanton-García J, Carney J, Böll B, Kochanek M, Jazmati N, et al. Clostridioides difficile infections in the intensive care unit: a monocentric cohort study. Infection. 2020;48(3):421–7. https://doi.org/10.1007/s15010-020-01413-8.CrossRefPubMedPubMedCentral

144.

Sartelli M, Di Bella S, McFarland LV, Khanna S, Furuya-Kanamori L, Abuzeid N, et al. 2019 update of the WSES guidelines for management of Clostridioides (Clostridium) difficile infection in surgical patients. World J Emerg Surg. 2019;14:8. https://doi.org/10.1186/s13017-015-0033-6.CrossRefPubMedPubMedCentral

145.

Farrell RJ, LaMont JT. Pathogenesis and clinical manifestations of Clostridium difficile diarrhea and colitis. Curr Top Microbiol Immunol. 2000;250:109–25. https://doi.org/10.1007/978-3-662-06272-2_6.CrossRefPubMed

146.

Britton RA, Young VB. Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. Gastroenterology. 2014;146(6):1547–53. https://doi.org/10.1053/j.gastro.2014.01.059.CrossRefPubMed

147.

Kachrimanidou M, Tsintarakis E. Insights into the role of human gut microbiota in Clostridioides difficile infection. Microorganisms. 2020;8(2):200. https://doi.org/10.3390/microorganisms8020200.CrossRefPubMedPubMedCentral

148.

Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect (Larchmt). 2013;14(1):73–156. https://doi.org/10.1089/sur.2013.9999.CrossRefPubMed

149.

Sartelli M, Boermeester MA, Cainzos M, Coccolini F, de Jonge SW, Rasa K, et al. Six long-standing questions about antibiotic prophylaxis in surgery. Antibiotics (Basel). 2023;12(5):908. https://doi.org/10.3390/antibiotics12050908.CrossRefPubMed

150.

Yin Y, Song T, Liao B, Luo Q, Zhou Z. Antibiotic prophylaxis in patients undergoing open mesh repair of inguinal hernia: a meta-analysis. Am Surg. 2012;78:359–65. https://doi.org/10.1177/000313481207800348.CrossRefPubMed

151.

Al Riyees L, Al Madani W, Firwana N, Balkhy HH, Ferwana M, Alkhudhayri A. Antibiotic prophylaxis against surgical site infection after open hernia surgery: a systematic review and meta-analysis. Eur Surg Res. 2021;62:121–33. https://doi.org/10.1159/000517404.CrossRefPubMed

152.

Erdas E, Medas F, Pisano G, Nicolosi A, Calò PG. Antibiotic prophylaxis for open mesh repair of groin hernia: systematic review and meta-analysis. Hernia. 2016;20:765–76. https://doi.org/10.1007/s10029-016-1536-0.CrossRefPubMed

153.

Orelio CC, van Hessen C, Sanchez-Manuel FJ, Aufenacker TJ, Scholten RJ. Antibiotic prophylaxis for prevention of postoperative wound infection in adults undergoing open elective inguinal or femoral hernia repair. Cochrane Database Syst Rev. 2020;4:CD003769. https://doi.org/10.1002/14651858.CD003769.pub5.CrossRefPubMed

154.

Mazaki T, Mado K, Masuda H, Shiono M. Antibiotic prophylaxis for the prevention of surgical site infection after tension-free hernia repair: a Bayesian and frequentist meta-analysis. J Am Coll Surg. 2013;217(788–801):e1–4. https://doi.org/10.1016/j.jamcollsurg.2013.07.386.CrossRef

155.

Boonchan T, Wilasrusmee C, McEvoy M, Attia J, Thakkinstian A. Network meta-analysis of antibiotic prophylaxis for prevention of surgical-site infection after groin hernia surgery. Br J Surg. 2017;104(2):e106–17. https://doi.org/10.1002/bjs.10441.CrossRefPubMed

156.

HerniaSurge Group. International guidelines for groin hernia management. Hernia. 2018;22:1–165. https://doi.org/10.1007/s10029-017-1668-x.CrossRef

157.

Reiffel AJ, Barie PS, Spector JA. A multi-disciplinary review of the potential association between closed-suction drains and surgical site infection. Surg Infect (Larchmt). 2013;14(3):244–69. https://doi.org/10.1089/sur.2011.126.CrossRefPubMed

158.

Leekha S, Terrell CL, Edson RS. General principles of antimicrobial therapy. Mayo Clin Proc. 2011;86(2):156–67. https://doi.org/10.4065/mcp.2010.0639.CrossRefPubMedPubMedCentral

159.

Cai T, Nesi G, Mazzoli S, Meacci F, Lanzafame P, Caciagli P, et al. Asymptomatic bacteriuria treatment is associated with a higher prevalence of antibiotic resistant strains in women with urinary tract infections. Clin Infect Dis. 2015;61(11):1655–61. https://doi.org/10.1093/cid/civ696.CrossRefPubMed

160.

Cash MC, Hile G, Johnson J, Stone T, Smith J, Ohl C, et al. Sustained impact of an antibiotic stewardship initiative targeting asymptomatic bacteriuria and pyuria in the emergency department. Antimicrob Steward Healthc Epidemiol. 2022;2(1):e148. https://doi.org/10.1017/ash.2022.289.CrossRefPubMedPubMedCentral

161.

Chabok A, Påhlman L, Hjern F, Haapaniemi S, Smedh K, AVOD Study Group. Randomized clinical trial of antibiotics in acute uncomplicated diverticulitis. Br J Surg. 2012;99(4):532–9. https://doi.org/10.1002/bjs.8688.CrossRefPubMed

162.

Daniels L, Ünlü Ç, de Korte N, van Dieren S, Stockmann HB, Vrouenraets BC, et al. Randomized clinical trial of observational versus antibiotic treatment for a first episode of CT-proven uncomplicated acute diverticulitis. Br J Surg. 2017;104(1):52–61. https://doi.org/10.1002/bjs.10309.CrossRefPubMed

163.

Jaung R, Nisbet S, Gosselink MP, Di Re A, Keane C, Lin A, et al. Antibiotics do not reduce length of hospital stay for uncomplicated diverticulitis in a pragmatic double-blind randomized trial. Clin Gastroenterol Hepatol. 2021;19(3):503-510.e1. https://doi.org/10.1016/j.cgh.2020.03.049.CrossRefPubMed

164.

Mali JP, Mentula PJ, Leppäniemi AK, Sallinen VJ. Symptomatic treatment for uncomplicated acute diverticulitis: a prospective cohort study. Dis Colon Rectum. 2016;59(6):529–34. https://doi.org/10.1097/DCR.0000000000000579.CrossRefPubMed

165.

Estrada Ferrer O, Ruiz Edo N, Hidalgo Grau LA, Abadal Prades M, Del Bas Rubia M, Garcia Torralbo EM, et al. Selective non-antibiotic treatment in sigmoid diverticulitis: Is it time to change the traditional approach? Tech Coloproctol. 2016;20(5):309–15. https://doi.org/10.1007/s10151-016-1464-0.CrossRefPubMed

166.

Barie PS, Kao LS, Moody M, Sawyer RG. Infection or inflammation: Are uncomplicated acute appendicitis, acute cholecystitis, and acute diverticulitis infectious diseases? Surg Infect (Larchmt). 2023;24(2):99–111. https://doi.org/10.1089/sur.2022.363.CrossRefPubMed

167.

Chabok A, Thorisson A, Nikberg M, Schultz JK, Sallinen V. Changing paradigms in the management of acute uncomplicated diverticulitis. Scand J Surg. 2021;110(2):180–6. https://doi.org/10.1177/14574969211011032.CrossRefPubMedPubMedCentral

168.

de Jonge SW, Gans SL, Atema JJ, Solomkin JS, Dellinger PE, Boermeester MA. Timing of preoperative antibiotic prophylaxis in 54,552 patients and the risk of surgical site infection: a systematic review and meta-analysis. Medicine. 2017;96:e6903. https://doi.org/10.1097/MD.0000000000006903.CrossRefPubMedPubMedCentral

169.

Wolfhagen N, Boldingh QJJ, de Lange M, Boermeester MA, de Jonge SW. Intraoperative redosing of surgical antibiotic prophylaxis in addition to preoperative prophylaxis versus single-dose prophylaxis for the prevention of surgical site infection: a meta-analysis and GRADE recommendation. Ann Surg. 2022;275:1050–7. https://doi.org/10.1097/SLA.0000000000005436.CrossRefPubMed

170.

Mazuski JE, Tessier JM, May AK, Sawyer RG, Nadler EP, Rosengart MR, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. Surg Infect (Larchmt). 2017;18(1):1–76. https://doi.org/10.1089/sur.2016.261.CrossRefPubMed

171.

McCarty TP, White CM, Pappas PG. Candidemia and invasive candidiasis. Infect Dis Clin N Am. 2021;35(2):389–413. https://doi.org/10.1016/j.idc.2021.03.007.CrossRef

172.

Kollef MH, Shorr AF, Bassetti M, Timsit JF, Micek ST, Michelson AP, et al. Timing of antibiotic therapy in the ICU. Crit Care. 2021;25(1):360. https://doi.org/10.1186/s13054-021-03787-z.CrossRefPubMedPubMedCentral

173.

Eachempati SR, Hydo LJ, Shou J, Barie PS. Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients? J Trauma. 2009;66(5):1343–8. https://doi.org/10.1097/TA.0b013e31819dca4e.CrossRefPubMed

174.

Zanichelli V, Sharland M, Cappello B, Moja L, Getahun H, Pessoa-Silva C, et al. The WHO AWaRe (Access, Watch, Reserve) antibiotic book and prevention of antimicrobial resistance. Bull World Health Organ. 2023;101(4):290–6. https://doi.org/10.2471/BLT.22.288614.CrossRefPubMedCentral

175.

Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, Cooperative Antimicrobial Therapy of Septic Shock Database Research Group, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest. 2009;136(5):1237–48. https://doi.org/10.1378/chest.09-0087.CrossRefPubMed

176.

Stuart B, Hounkpatin H, Becque T, Yao G, Zhu S, Alonso-Coello P, et al. Delayed antibiotic prescribing for respiratory tract infections: individual patient data meta-analysis. BMJ. 2021;373:n808. https://doi.org/10.1136/bmj.n808.CrossRefPubMedPubMedCentral

177.

Hranjec T, Rosenberger LH, Swenson B, Metzger R, Flohr TR, Politano AD, et al. Aggressive versus conservative initiation of antimicrobial treatment in critically ill surgical patients with suspected intensive-care-unit-acquired infection: a quasi-experimental, before and after observational cohort study. Lancet Infect Dis. 2012;12(10):774–80. https://doi.org/10.1016/S1473-3099(12)70151-2.CrossRefPubMedPubMedCentral

178.

Paul M, Shani V, Muchtar E, Kariv G, Robenshtok E, Leibovici L. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother. 2010;54(11):4851–63. https://doi.org/10.1128/AAC.00627-10.CrossRefPubMedPubMedCentral

179.

Bassetti M, Rello J, Blasi F, Goossens H, Sotgiu G, Tavoschi L, et al. Systematic review of the impact of appropriate versus inappropriate initial antibiotic therapy on outcomes of patients with severe bacterial infections. Int J Antimicrob Agents. 2020;56(6):106184. https://doi.org/10.1016/j.ijantimicag.2020.106184.CrossRefPubMed

180.

Weinberger J, Rhee C, Klompas M. A critical analysis of the literature on time-to-antibiotics in suspected sepsis. J Infect Dis. 2020;222(Suppl 2):S110–8. https://doi.org/10.1093/infdis/jiaa146.CrossRefPubMed

181.

Seymour CW, Gesten F, Prescott HC, Friedrich ME, Iwashyna TJ, Phillips GS, et al. Time to treatment and mortality during mandated emergency care for sepsis. N Engl J Med. 2017;376(23):2235–44. https://doi.org/10.1056/NEJMoa1703058.CrossRefPubMedPubMedCentral

182.

Liu VX, Fielding-Singh V, Greene JD, Baker JM, Iwashyna TJ, Bhattacharya J, et al. The timing of early antibiotics and hospital mortality in sepsis. Am J Respir Crit Care Med. 2017;196(7):856–63. https://doi.org/10.1164/rccm.201609-1848OC.CrossRefPubMedPubMedCentral

183.

Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021;49(11):e1063–143. https://doi.org/10.1097/CCM.0000000000005337.CrossRefPubMed

184.

Blot S, Depuydt P, Vogelaers D, Decruyenaere J, De Waele J, Hoste E, et al. Colonization status and appropriate antibiotic therapy for nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in an intensive care unit. Infect Control Hosp Epidemiol. 2005;26(6):575–9. https://doi.org/10.1086/502575.CrossRefPubMed

185.

Brusselaers N, Labeau S, Vogelaers D, Blot S. Value of lower respiratory tract surveillance cultures to predict bacterial pathogens in ventilator-associated pneumonia: systematic review and diagnostic test accuracy meta-analysis. Intensive Care Med. 2013;39(3):365–75. https://doi.org/10.1007/s00134-012-2759-x.CrossRefPubMed

186.

Michel F, Franceschini B, Berger P, Arnal JM, Gainnier M, Sainty JM, et al. Early antibiotic treatment for BAL-confirmed ventilator-associated pneumonia: a role for routine endotracheal aspirate cultures. Chest. 2005;127(2):589–97. https://doi.org/10.1378/chest.127.2.589.CrossRefPubMed

187.

Depuydt PO, Blot SI, Benoit DD, Claeys GW, Verschraegen GL, Vandewoude KH, et al. Antimicrobial resistance in nosocomial bloodstream infection associated with pneumonia and the value of systematic surveillance cultures in an adult intensive care unit. Crit Care Med. 2006;34(3):653–9. https://doi.org/10.1097/01.CCM.0000201405.16525.34.CrossRefPubMed

188.

Depuydt P, Benoit D, Vogelaers D, Decruyenaere J, Vandijck D, Claeys G, et al. Systematic surveillance cultures as a tool to predict involvement of multidrug antibiotic resistant bacteria in ventilator-associated pneumonia. Intensive Care Med. 2008;34(4):675–82. https://doi.org/10.1007/s00134-007-0953-z.CrossRefPubMed

189.

Müller M, Dela Peña A, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother. 2004;48:1441–53. https://doi.org/10.1128/AAC.48.5.1441-1453.2004.CrossRefPubMedPubMedCentral

190.

Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet. 2005;44(10):1009–34. https://doi.org/10.2165/00003088-200544100-00002.CrossRefPubMed

191.

Gonzalez D, Schmidt S, Derendorf H. Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents. Clin Microbiol Rev. 2013;26:274–88. https://doi.org/10.1128/CMR.00092-12.CrossRefPubMedPubMedCentral

192.

Levison ME. Pharmacodynamics of antimicrobial drugs. Infect Dis Clin N Am. 2004;18:451–65. https://doi.org/10.1016/j.idc.2009.06.008.CrossRef

193.

Buijk SL, Gyssens IC, Mouton JW, Van Vliet A, Verbrugh HA, Bruining HA. Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections. J Antimicrob Chemother. 2002;49:121–8. https://doi.org/10.1093/jac/49.1.121.CrossRefPubMed

194.

Dahyot-Fizelier C, Lefeuvre S, Laksiri L, Marchand S, Sawchuk RJ, Couet W, et al. Kinetics of imipenem distribution into the peritoneal fluid of patients with severe peritonitis studied by microdialysis. Clin Pharmacokinet. 2010;49:323–34. https://doi.org/10.2165/11319370-000000000-00000.CrossRefPubMed

195.

Karjagin J, Lefeuvre S, Oselin K, Kipper K, Marchand S, Tikkerberi A, et al. Pharmacokinetics of meropenem determined by microdialysis in the peritoneal fluid of patients with severe peritonitis associated with septic shock. Clin Pharmacol Ther. 2008;83:452–9. https://doi.org/10.1038/sj.clpt.6100312.CrossRefPubMed

196.

Pea F, Viale P. Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock-does the dose matter? Crit Care. 2009;13(3):214. https://doi.org/10.1186/cc7774.CrossRefPubMedPubMedCentral

197.

Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient-concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev. 2014;77:3–11. https://doi.org/10.1016/j.addr.2014.07.006.CrossRefPubMed

198.

Bland CM, Pai MP, Lodise TP. Reappraisal of contemporary pharmacokinetic and pharmacodynamic principles for informing aminoglycoside dosing. Pharmacotherapy. 2018;38(12):1229–38. https://doi.org/10.1002/phar.2193.CrossRefPubMed

199.

Pagkalis S, Mantadakis E, Mavros MN, Ammari C, Falagas ME. Pharmacological considerations for the proper clinical use of aminoglycosides. Drugs. 2011;71(17):2277–94. https://doi.org/10.2165/11597020-000000000-00000.CrossRefPubMed

200.

Al-Dorzi HM, Al Harbi SA, Arabi YM. Antibiotic therapy of pneumonia in the obese patient: dosing and delivery. Curr Opin Infect Dis. 2014;27(2):165–73. https://doi.org/10.1097/QCO.0000000000000045.CrossRefPubMedPubMedCentral

201.

Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, Mueller BA, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835–64. https://doi.org/10.1093/ajhp/zxaa036.CrossRefPubMed

202.

McMullan BJ, Andresen D, Blyth CC, Avent ML, Bowen AC, Britton PN, et al. Antibiotic duration and timing of the switch from intravenous to oral route for bacterial infections in children: systematic review and guidelines. Lancet Infect Dis. 2016;16:E139–52. https://doi.org/10.1016/S1473-3099(16)30024-X.CrossRefPubMed

203.

Landersdorfer CB, Gwee A, Nation RL. Clinical pharmacological considerations in an early intravenous to oral antibiotic switch: Are barriers real or simply perceived? Clin Microbiol Infect. 2023 Apr 12:S1198–743X(23)00179–9. doi: https://doi.org/10.1016/j.cmi.2023.04.009. Online ahead of print.

204.

Quintiliani R, Grant E, Quintiliani R Jr. Transitional (intravenous to oral) antibiotic therapy. J Med Liban. 2000;48(4):233–40.PubMed

205.

Al-Hasan MN, Rac H. Transition from intravenous to oral antimicrobial therapy in patients with uncomplicated and complicated bloodstream infections. Clin Microbiol Infect. 2020;26:299–306. https://doi.org/10.1016/j.cmi.2019.05.012.CrossRefPubMed

206.

Fishbein SRS, Mahmud B, Dantas G. Antibiotic perturbations to the gut microbiome. Nat Rev Microbiol. 2023. https://doi.org/10.1038/s41579-023-00933-y.CrossRefPubMed

207.

Tabah A, Bassetti M, Kollef MH, Zahar JR, Paiva JA, Timsit JF, et al. Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP). Intensive Care Med. 2020;46(2):245–65. https://doi.org/10.1007/s00134-019-05866-w.CrossRefPubMed

208.

Silva BN, Andriolo RB, Atallah AN, Salomão R. De-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shock. Cochrane Database Syst Rev. 2013;2013(3):CD007934. https://doi.org/10.1002/14651858.CD007934.pub3.CrossRefPubMedPubMedCentral

209.

Niederman MS. De-escalation therapy in ventilator-associated pneumonia. Curr Opin Crit Care. 2006;12(5):452–7. https://doi.org/10.1097/01.ccx.0000244126.84989.a2.CrossRefPubMed

210.

Rello J, Vidaur L, Sandiumenge A, Rodríguez A, Gualis B, Boque C, et al. De-escalation therapy in ventilator-associated pneumonia. Crit Care Med. 2004;32(11):2183–90. https://doi.org/10.1097/01.ccm.0000145997.10438.28.CrossRefPubMed

211.

De Waele JJ, Schouten J, Beovic B, Tabah A, Leone M. Antimicrobial de-escalation as part of antimicrobial stewardship in intensive care: no simple answers to simple questions-a viewpoint of experts. Intensive Care Med. 2020;46(2):236–44. https://doi.org/10.1007/s00134-019-05871-z.CrossRefPubMedPubMedCentral

212.

Lim C, Ashley EA, Hamers RL, Turner P, Kesteman T, Akech S, et al. Surveillance strategies using routine microbiology for antimicrobial resistance in low- and middle-income countries. Clin Microbiol Infect. 2021;27(10):1391–9. https://doi.org/10.1016/j.cmi.2021.05.037.CrossRefPubMedPubMedCentral

213.

Cansizoglu MF, Tamer YT, Farid M, Koh AY, Toprak E. Rapid ultrasensitive detection platform for antimicrobial susceptibility testing. PLoS Biol. 2019;17(5):e3000291. https://doi.org/10.1371/journal.pbio.3000291.CrossRefPubMedPubMedCentral

214.

Anjum MF, Zankari E, Hasman H. Molecular methods for detection of antimicrobial resistance. Microbiol Spectr. 2017. https://doi.org/10.1128/microbiolspec.ARBA-0011-2017.CrossRefPubMed

215.

Burnham CD, Leeds J, Nordmann P, O’Grady J, Patel J. Diagnosing antimicrobial resistance. Nat Rev Microbiol. 2017;15(11):697–703. https://doi.org/10.1038/nrmicro.2017.103.CrossRefPubMed

216.

Giordano C, Piccoli E, Brucculeri V, Barnini S. A prospective evaluation of two rapid phenotypical antimicrobial susceptibility technologies for the diagnostic stewardship of sepsis. Biomed Res Int. 2018;2018:6976923. https://doi.org/10.1155/2018/6976923.CrossRefPubMedPubMedCentral

217.

Cals JW, Ament AJ, Hood K, Butler CC, Hopstaken RM, Wassink GF, et al. C-reactive protein point of care testing and physician communication skills training for lower respiratory tract infections in general practice: economic evaluation of a cluster randomized trial. J Eval Clin Pract. 2011;17(6):1059–69. https://doi.org/10.1111/j.1365-2753.2010.01472.x.CrossRefPubMed

218.

Holmes EAF, Harris SD, Hughes A, Craine N, Hughes DA. Cost-effectiveness analysis of the use of point-of-care C-reactive protein testing to reduce antibiotic prescribing in primary care. Antibiotics (Basel). 2018;7(4):106. https://doi.org/10.3390/antibiotics7040106.CrossRefPubMed

219.

Hunter R. Cost-effectiveness of point-of-care C-reactive protein tests for respiratory tract infection in primary care in England. Adv Ther. 2015;32:69–85. https://doi.org/10.1007/s12325-015-0180-x.CrossRefPubMedPubMedCentral

220.

Global guidelines for the prevention of surgical site infection. Geneva: World Health Organization; 2018. Web Appendix 25. Summary of a systematic review on surgical antibiotic prophylaxis prolongation. https://www.ncbi.nlm.nih.gov/books/NBK536429/. Accessed 12 July 2023.

221.

Calderwood MS, Anderson DJ, Bratzler DW, Dellinger EP, Garcia-Houchins S, Maragakis LL, et al. Strategies to prevent surgical site infections in acute-care hospitals: 2022 Update. Infect Control Hosp Epidemiol. 2023;44(5):695–720. https://doi.org/10.1017/ice.2023.67.CrossRefPubMed

222.

de Jonge SW, Boldingh QJJ, Solomkin JS, Dellinger EP, Egger M, Salanti G, et al. Effect of postoperative continuation of antibiotic prophylaxis on the incidence of surgical site infection: a systematic review and meta-analysis. Lancet Infect Dis. 2020;20(10):1182–92. https://doi.org/10.1016/S1473-3099(20)30084-0.CrossRefPubMed

223.

Branch-Elliman W, O’Brien W, Strymish J, Itani K, Wyatt C, Gupta K. Association of duration and type of surgical prophylaxis with antimicrobial-associated adverse events. JAMA Surg. 2019;154:590–8. https://doi.org/10.1001/jamasurg.2019.0569.CrossRefPubMedPubMedCentral

224.

Brink AJ, Messina AP, Feldman C, Richards GA, van den Bergh D, Netcare Antimicrobial Stewardship Study Alliance. From guidelines to practice: a pharmacist-driven prospective audit and feedback improvement model for peri-operative antibiotic prophylaxis in 34 South African hospitals. J Antimicrob Chemother. 2017;72(4):1227–34. https://doi.org/10.1093/jac/dkw523.CrossRefPubMed

225.

Spellberg B, Rice LB. Duration of antibiotic therapy: shorter is better. Ann Intern Med. 2019;171(3):210–1. https://doi.org/10.7326/M19-1509.CrossRefPubMedPubMedCentral

226.

Langford BJ, Nisenbaum R, Brown KA, Chan A, Downing M. Antibiotics: easier to start than to stop? Predictors of antimicrobial stewardship recommendation acceptance. Clin Microbiol Infect. 2020;26(12):1638–43. https://doi.org/10.1016/j.cmi.2020.07.048.CrossRefPubMed

227.

Spellberg B. The new antibiotic mantra-“shorter Is better.” JAMA Intern Med. 2016;176(9):1254–5. https://doi.org/10.1001/jamainternmed.2016.3646.CrossRefPubMedPubMedCentral

228.

Sawyer RG, Claridge JA, Nathens AB, Rotstein OD, Duane TM, Evans HL, STOP-IT Trial Investigators, et al. Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med. 2015;372(21):1996–2005. https://doi.org/10.1056/NEJMoa1411162.CrossRefPubMedPubMedCentral

229.

Montravers P, Tubach F, Lescot T, Veber B, Esposito-Farèse M, Seguin P, et al. Short-course antibiotic therapy for critically ill patients treated for postoperative intra-abdominal infection: the DURAPOP randomised clinical trial. Intensive Care Med. 2018;44(3):300–10. https://doi.org/10.1007/s00134-018-5088-x.CrossRefPubMed

230.

Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003;290(19):2588–98. https://doi.org/10.1001/jama.290.19.2588.CrossRefPubMed

231.

Dimopoulos G, Poulakou G, Pneumatikos IA, Armaganidis A, Kollef MH, Matthaiou DK. Short- vs long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis. Chest. 2013;144(6):1759–67. https://doi.org/10.1378/chest.13-0076.CrossRefPubMed

232.

Martin-Loeches I, Rodriguez AH, Torres A. New guidelines for hospital-acquired pneumonia/ventilator-associated pneumonia: USA vs. Europe. Curr Opin Crit Care. 2018;24(5):347–52. https://doi.org/10.1097/MCC.0000000000000535.CrossRefPubMed

233.

Mo Y, West TE, MacLaren G, Booraphun S, Li AY, Kayastha G, et al. Reducing antibiotic treatment duration for ventilator-associated pneumonia (REGARD-VAP): a trial protocol for a randomised clinical trial. BMJ Open. 2021;11(5):e050105. https://doi.org/10.1136/bmjopen-2021-050105.CrossRefPubMedPubMedCentral

234.

Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus 14 days of antibiotic therapy for uncomplicated gram-negative bacteremia: a noninferiority randomized controlled trial. Clin Infect Dis. 2019;69(7):1091–8. https://doi.org/10.1093/cid/ciy1054.CrossRefPubMed

235.

Daneman N, Rishu AH, Pinto R, Aslanian P, Bagshaw SM, Carignan A, et al. 7 versus 14 days of antibiotic treatment for critically ill patients with bloodstream infection: a pilot randomized clinical trial. Trials. 2018;19(1):111. https://doi.org/10.1186/s13063-019-4033-9.CrossRefPubMedPubMedCentral

236.

Chotiprasitsakul D, Han JH, Cosgrove SE, Harris AD, Lautenbach E, Conley AT, et al. Comparing the outcomes of adults with Enterobacteriaceae bacteremia receiving short-course versus prolonged-course antibiotic therapy in a multicenter, propensity score-matched cohort. Clin Infect Dis. 2018;66(2):172–7. https://doi.org/10.1093/cid/cix767.CrossRefPubMed

237.

Tansarli GS, Andreatos N, Pliakos EE, Mylonakis E. A systematic review and meta-analysis of antibiotic treatment duration for bacteremia due to Enterobacteriaceae. Antimicrob Agents Chemother. 2019;63(5):e02495-e2518. https://doi.org/10.1128/AAC.02495-18.CrossRefPubMedPubMedCentral

238.

Fabre V, Amoah J, Cosgrove SE, Tamma PD. Antibiotic therapy for Pseudomonas aeruginosa bloodstream infections: How long is long enough? Clin Infect Dis. 2019;69(11):2011–4. https://doi.org/10.1093/cid/ciz223.CrossRefPubMedPubMedCentral

239.

von Dach E, Albrich WC, Brunel AS, Prendki V, Cuvelier C, Flury D, et al. Effect of C-reactive protein-guided antibiotic treatment duration, 7-day treatment, or 14-day treatment on 30-day clinical failure rate in patients with uncomplicated gram-negative bacteremia: a randomized clinical trial. JAMA. 2020;323(21):2160–9. https://doi.org/10.1001/jama.2020.6348.CrossRef

240.

Hepburn MJ, Dooley DP, Skidmore PJ, Ellis MW, Starnes WF, Hasewinkle WC. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med. 2004;164(15):1669–74. https://doi.org/10.1001/archinte.164.15.1669.CrossRefPubMed

241.

Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, Infectious Diseases Society of America, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-52. https://doi.org/10.1093/cid/ciu444.CrossRefPubMed

242.

Brink AJ, Richards G. Best practice: antibiotic decision-making in ICUs. Curr Opin Crit Care. 2020;26(5):478–88. https://doi.org/10.1097/MCC.0000000000000752.CrossRefPubMed

243.

Khilnani GC, Tiwari P, Zirpe KG, Chaudhry D, Govil D, Dixit S, et al. Guidelines for the use of procalcitonin for rational use of antibiotics. Indian J Crit Care Med. 2022;26(Suppl 2):S77–94. https://doi.org/10.5005/jp-journals-10071-24326.CrossRefPubMedPubMedCentral

244.

Wirz Y, Meier MA, Bouadma L, Luyt CE, Wolff M, Chastre J, et al. Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of randomized trials. Crit Care. 2018;22(1):191. https://doi.org/10.1186/s13054-018-2125-2127.CrossRefPubMedPubMedCentral

245.

Sartelli M, Coccolini F, Kluger Y, Agastra E, Abu-Zidan FM, Abbas AES, et al. WSES/GAIS/WSIS/SIS-E/AAST global clinical pathways for patients with skin and soft tissue infections. World J Emerg Surg. 2022;17(1):3. https://doi.org/10.1186/s13017-022-00406-2.CrossRefPubMedPubMedCentral

246.

Sartelli M, Coccolini F, Kluger Y, Agastra E, Abu-Zidan FM, Abbas AES, et al. WSES/GAIS/SIS-E/WSIS/AAST global clinical pathways for patients with intra-abdominal infections. World J Emerg Surg. 2021;16(1):49. https://doi.org/10.1186/s13017-021-00387-8.CrossRefPubMedPubMedCentral

247.

Kao LS, Ball CG, Chaudhury PK, for Members of the Evidence Based Reviews in Surgery Group. Evidence-based reviews in surgery: Early cholecystectomy for cholecystitis. Ann Surg. 2018;268(6):940–2. https://doi.org/10.1097/SLA.0000000000002867.CrossRefPubMed

248.

De Waele JJ. Early source control in sepsis. Langenbecks Arch Surg. 2010;395:489–94. https://doi.org/10.1007/s00423-010-0650-1.CrossRefPubMed

249.

Martínez ML, Ferrer R, Torrents E, Guillamat-Prats R, Gomà G, Suárez D, et al. Impact of source control in patients with severe sepsis and septic shock. Crit Care Med. 2017;45(1):11–9. https://doi.org/10.1097/CCM.0000000000002011.CrossRefPubMed

250.

Bloos F, Rüddel H, Thomas-Rüddel D, Schwarzkopf D, Pausch C, Harbarth S, et al. Effect of a multifaceted educational intervention for anti-infectious measures on sepsis mortality: a cluster randomized trial. Intensive Care Med. 2017;43(11):1602–12. https://doi.org/10.1007/s00134-017-4782-4.CrossRefPubMed

251.

Reitz KM, Kennedy J, Li SR, Handzel R, Tonetti DA, Neal MD, et al. association between time to source control in sepsis and 90-day mortality. JAMA Surg. 2022;157(9):817–26. https://doi.org/10.1001/jamasurg.2022.2761.CrossRefPubMedPubMedCentral

252.

De Pascale G, Antonelli M, Deschepper M, Arvaniti K, Blot K, Brown BC, et al. Poor timing and failure of source control are risk factors for mortality in critically ill patients with secondary peritonitis. Intensive Care Med. 2022;48(11):1593–606. https://doi.org/10.1007/s00134-022-06883-y.CrossRefPubMed

253.

Tabah A, Buetti N, Staiquly Q, EUROBACT-2 Study Group, ESICM, ESCMID ESGCIP and the OUTCOMEREA Network, et al. Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study. Intensive Care Med. 2023. https://doi.org/10.1007/s00134-012-2695-9.CrossRefPubMedPubMedCentral

254.

De Waele JJ, Girardis M, Martin-Loeches I. Source control in the management of sepsis and septic shock. Intensive Care Med. 2023;48(12):1799–802. https://doi.org/10.1007/s00134-022-06852-5.CrossRef

255.

Barie PS, Williams MD, McCollam JS, Bates BM, Qualy RL, Lowry SF, PROWESS Surgical Evaluation Committee, et al. Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis. Am J Surg. 2004;188(3):212–20. https://doi.org/10.1016/j.amjsurg.2004.06.008.CrossRefPubMed

256.

van de Groep K, Verhoeff TL, Verboom DM, Bos LD, Schultz MJ, Bonten MJM, et al. Epidemiology and outcomes of source control procedures in critically ill patients with intra-abdominal infection. J Crit Care. 2019;52:258–64. https://doi.org/10.1016/j.jcrc.2019.02.029.CrossRefPubMed

257.

European Center for Disease Prevention and Control. Healthcare-associated infections surveillance network (HAI-Net). https://www.ecdc.europa.eu/en/about-us/partnerships-and-networks/disease-and-laboratory-networks/hai-net. Accessed 12 July 2023.

258.

Centers for Disease Control and Prevention. National Healthcare Safety Network (NHSN). https://www.cdc.gov/nhsn/index.html. Accessed 12 July 2023.

259.

European Center for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2022–2020 data. www.ecdc.europa.eu/en/publications-data/antimicrobial-resistance-surveillance-europe-2022-2020-data. Accessed 12 July 2023.

260.

Global antimicrobial resistance and use surveillance system (GLASS) report: 2022. Geneva: World Health Organization; 2022. www.who.int/publications/i/item/9789240062702. Accessed 12 July 2023.

261.

Maugeri A, Barchitta M, Puglisi F, Agodi A. Socio-economic, governance and health indicators shaping antimicrobial resistance: an ecological analysis of 30 European countries. Glob Health. 2023;19(1):12. https://doi.org/10.1186/s12992-023-00913-0.CrossRef

262.

Pallares C, Hernández-Gómez C, Appel TM, Escandón K, Reyes S, Salcedo S, et al. Impact of antimicrobial stewardship programs on antibiotic consumption and antimicrobial resistance in four Colombian healthcare institutions. BMC Infect Dis. 2022;22(1):420. https://doi.org/10.1186/s12879-022-07410-6.CrossRefPubMedPubMedCentral

263.

Klein EY, Van Boeckel TP, Martinez EM, Pant S, Gandra S, Levin SA, et al. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci USA. 2018;115(15):E3463–70. https://doi.org/10.1073/pnas.1717295115.CrossRefPubMedPubMedCentral

264.

Rawson TM, Moore LS, Tivey AM, Tsao A, Gilchrist M, Charani E, et al. Behaviour change interventions to influence antimicrobial prescribing: a cross-sectional analysis of reports from UK state-of-the-art scientific conferences. Antimicrob Resist Infect Control. 2017;6(1):11. https://doi.org/10.1186/s13756-019-0603-6.CrossRefPubMedPubMedCentral

265.

Majumder MAA, Rahman S, Cohall D, Bharatha A, Singh K, Haque M, Gittens-St Hilaire M. Antimicrobial stewardship: fighting antimicrobial resistance and protecting global public health. Infect Drug Resist. 2020;13:4713–38. https://doi.org/10.2147/IDR.S290835.CrossRefPubMedPubMedCentral

266.

Majumder MAA, Singh K, Hilaire MG, Rahman S, Sa B, Haque M. Tackling antimicrobial resistance by promoting antimicrobial stewardship in medical and allied health professional curricula. Expert Rev Anti Infect Ther. 2020;18(12):1245–58. https://doi.org/10.1080/14787210.2020.1796638.CrossRefPubMed

267.

Alkhuzaei AMJB, Salama RE, Eljak IEI, Chehab MA, Selim NA. Perceptions and practice of physicians and pharmacists regarding antibiotic misuse at primary health centres in Qatar: a cross-sectional study. J Taibah Univ Med Sci. 2017;13(1):77–82. https://doi.org/10.1016/j.jtumed.2017.09.001.CrossRefPubMedPubMedCentral

268.

Mangione SR, McGlynn E, Elliot M. Parent expectations for antibiotics, physician–parent communication, and satisfaction. Arch Pediatr Adolesc Med. 2001;7(155):800–6.CrossRef

269.

Saleem Z, Godman B, Cook A, et al. Ongoing efforts to improve antimicrobial utilization in hospitals among African countries and implications for the future. Antibiotics (Basel). 2022;11(12):1824. https://doi.org/10.3390/antibiotics11121824.CrossRefPubMed

270.

Sartelli M, Labricciosa FM, Barbadoro P, Pagani L, Ansaloni L, Brink AJ, et al. The global alliance for infections in surgery: defining a model for antimicrobial stewardship-results from an international cross-sectional survey. World J Emerg Surg. 2017;12:34. https://doi.org/10.1186/s13017-017-0145-2.CrossRefPubMedPubMedCentral

271.

Davey P, Brown E, Charani E, Fenelon L, Gould IM, Holmes A, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev. 2013;4:CD003543. https://doi.org/10.1002/14651858.CD003543.pub4.CrossRef

272.

Rawson TM, Moore LS, Gilchrist MJ, Holmes AH. Antimicrobial stewardship: Are we failing in cross-specialty clinical engagement? J Antimicrob Chemother. 2016;71:554–9. https://doi.org/10.1093/jac/dkv337.CrossRefPubMed

273.

Howard P, Pulcini C, Levy Hara G, West RM, Gould IM, Harbarth S, et al. An international cross-sectional survey of antimicrobial stewardship programmes in hospitals. J Antimicrob Chemother. 2015;70(4):1245–55. https://doi.org/10.1093/jac/dku497.CrossRefPubMed

274.

Raval MV, Bentrem DJ, Eskandari MK, Ingraham AM, Hall BL, Randolph B, et al. The role of surgical champions in the American College of Surgeons National Surgical Quality Improvement Program-a national survey. J Surg Res. 2011;166(1):e15-25. https://doi.org/10.1016/j.jss.2010.10.036.CrossRefPubMed

275.

Wunderink RG, Srinivasan A, Barie PS, Chastre J, Dela Cruz CS, Douglas IS, et al. Antibiotic stewardship in the intensive care unit. An official American Thoracic Society workshop report in collaboration with the AACN, CHEST, CDC, and SCCM. Ann Am Thorac Soc. 2020;17(5):531–40. https://doi.org/10.1513/AnnalsATS.202003-188ST.CrossRefPubMedPubMedCentral

276.

May L, Martín Quirós A, Ten Oever J, Hoogerwerf J, Schoffelen T, Schouten J. Antimicrobial stewardship in the emergency department: characteristics and evidence for effectiveness of interventions. Clin Microbiol Infect. 2021;27(2):204–9. https://doi.org/10.1016/j.cmi.2020.10.028.CrossRefPubMed

277.

Paul M, Pulia M, Pulcini C. Antibiotic stewardship in the emergency department: not to be overlooked. Clin Microbiol Infect. 2021;27(2):172–4. https://doi.org/10.1016/j.cmi.2020.11.015.CrossRefPubMed

278.

Castro-Sánchez E, Gilchrist M, Ahmad R, Courtenay M, Bosanquet J, Holmes AH. Nurse roles in antimicrobial stewardship: lessons from public sectors models of acute care service delivery in the United Kingdom. Antimicrob Resist Infect Control. 2019;22(8):162.CrossRef

279.

Kumar M, Sarma DK, Shubham S, Kumawat M, Verma V, Nina PB, et al. Futuristic non-antibiotic therapies to combat antibiotic resistance: a review. Front Microbiol. 2021;12:609459. https://doi.org/10.3389/fmicb.2021.609459.CrossRefPubMedPubMedCentral

280.

Catho G, Sauser J, Coray V, Da Silva S, Elzi L, Harbarth S, et al. Impact of interactive computerised decision support for hospital antibiotic use (COMPASS): an open-label, cluster-randomised trial in three Swiss hospitals. Lancet Infect Dis. 2022;22(10):1493–502. https://doi.org/10.1016/S1473-3099(22)00308-5.CrossRefPubMedPubMedCentral

281.

Curtis CE, Al Bahar F, Marriott JF. The effectiveness of computerised decision support on antibiotic use in hospitals: a systematic review. PLoS ONE. 2017;12(8):e0183062. https://doi.org/10.1371/journal.pone.0183062.CrossRefPubMedPubMedCentral

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Ten golden rules for optimal antibiotic use in hospital settings: the WARNING call to action

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2023

WSES consensus guidelines on sigmoid volvulus management

A prospective multicentre study evaluating the outcomes of the abdominal wall dehiscence repair using posterior component separation with transversus abdominis muscle release reinforced by a retro-muscular mesh: filling a step

The optimal timing and intervention to reduce mortality for necrotizing pancreatitis: a systematic review and network meta-analysis

Diagnostic accuracy of biomarkers to detect acute mesenteric ischaemia in adult patients: a systematic review and meta-analysis

Source control in emergency general surgery: WSES, GAIS, SIS-E, SIS-A guidelines

Limb salvage and survival after urgent surgical treatment of popliteal artery aneurysm